Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Commenced operations in flood-affected Himachal Pradesh
Research released at UN General Assembly week shows tests predicting heart disease and diabetes are among lowest cost solutions for improving Indian health
The VitalDose Drug Delivery Platform has been used in patient-centric dose forms in women’s health for over two decades
Rs. 64000 crores are being invested across the 750 districts of India, to create a more resilient healthcare system in the country
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
Good momentum in commercial CDMO business
Subscribe To Our Newsletter & Stay Updated